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Abstract
Background: Preeclampsia is one of the most common pregnancy complications,
which is one of the major causes of fetal and maternal mortality.
Objective: To compare the serum Brain Natriuretic Peptide (BNP) level in patients with
severe preeclampsia and normal pregnancy and investigate associated cardiovascular
complications.
Materials and Methods: This case-control study was performed on 94 women with
a singleton pregnancy (severe preeclampsia and normal pregnancy) at Imam Reza
Hospital in Mashhad, Iran. The venous blood samples were collected to evaluate the
serum BNP level. All patients were subjected to echocardiography performed by a
single cardiologist.
Results: The mean pro-BNP levels were 480.36 ± 754.52 and 67.46 ± 106.24 pg/dL
in the severe preeclampsia and normal pregnancy patients, respectively (p < 0.001).
However, adjusted BNP for maternal and gestational age was not different in the
two groups (ANCOVA, p = 0.69). Furthermore, the two study groups showed no
significant difference in terms of the cardiac parameters, including ejection fraction (EF),
left ventricle end-diastolic and -systolic diameters (LVEDD and LVESD, respectively),
tricuspid annular plane systolic excursion (TAPSE), and ratio of the early transmitral
flow velocity to the early diastolic tissue velocity (E/Em). However, the serum BNP level
showed a significant correlation with EF (r = -0.39, p = 0.008), TAPSE (r = -0.47, p =
0.001), and E/Em ratio (r = 0.48, p = 0.001) in patients with severe preeclampsia.
Conclusion: It seems that BNP can be used as a predictor for some of the main cardiac
functional indices (i.e., E/Em, EF, and TAPSE) in severe preeclampsia patients.
Key words: Brain natriuretic peptide, Echocardiography, Stroke volume, Pre-
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1. Introduction
Gestational hypertension and preeclampsia are
among the most prevalent medical problems dur-
ing pregnancy, which mostly occur in the young
and nulliparous females (1, 2). Preeclampsia is one
of the main risk factors for maternal mortality along
with maternal and fetal-neonatal complications (3).
This condition complicates 5–8% of the pregnan-
cies and has an unknownetiology (4). Preeclampsia
occurs early in pregnancy through hidden patho-
physiological changes that accelerate during preg-
nancy and ultimately becomes clinically apparent
(2). Several investigations have been conducted to
find the predictive factors of preeclampsia. How-
ever, there is no reliable, valid, and cost-effective
method for predicting this condition. Preeclampsia
can be diagnosed in its early stages only through
the implementation of planned prenatal care (5).
The first step in the prevention of preeclampsia
is the early detection of women at risk of this
complication. Therefore, the use of an appropriate
diagnostic test that can help identify the patients
at risk is of paramount importance. Such a test
can play a significant role in the reduction of
maternal and fetal mortality and morbidity (6).
Severe cardiovascular dysfunctions are common in
preeclampsia syndrome. These disorders increase
the cardiac output due to high blood pressure
and induce a significant negative impact on the
cardiac input by the pathologic reduction of hypo-
volemia during pregnancy. The echocardiography
of myocardial function and the clinical assessment
of ventricular function should be considered when
evaluating cardiac function in preeclampsia (7).
Brain natriuretic peptide (BNP) is a polypeptide,
which is secreted as a pre-pro BNP by the cardiac
ventricle in response to excessive stretching of the
heart muscle cells in the ventricular myocarditis
and slightly stored in the granules (8–10). It has
been recently demonstrated that the patients with
preeclampsia have an elevated BNP level as com-
pared to those with normal pregnancy, which is
indicative of subclinical vascular disorders in these
patients (11). Furthermore, the previous studies have
demonstrated a direct relationship between the
BNP level and the severity of preeclampsia and
obstetrical complications, such as preterm delivery
(12). According to various studies, cardiovascular
disorders, such as increased systemic vascular
resistance and left ventricular pressure, decreased
heart rate, left ventricular diastolic dysfunction, and
increased left ventricular mass index are associ-
ated with the elevation of BNP in preeclampsia.
However, these studies have included both severe
and non-severe preeclampsia (12).
With this background in mind, the present
study aimed to compare the serum BNP level
in patients with severe preeclampsia and normal
pregnancy and investigating cardiovascular com-
plications. The findings of this study may be helpful
in introducing BNP as amarker for the identification
of patients requiring cardiac evaluation.
2. Materials and Methods
This case-control study was performed on 94
women with singleton pregnancy at Imam Reza
Hospital in Mashhad, Iran from September 2015 to
November 2016. The study population who were
selected among referral patients were patients with
preeclampsia and those with normal pregnancy.
The sample size of this study was estimated as
45 patients in each group based on a study
conducted by Hamad and colleagues (13) and the
formula for comparing the two means with an
alpha of 5%, power of 80%, and 10% for drop
out. The inclusion criteria were women with severe
preeclampsia which is defined as the presence
of one of the following signs or symptoms in the
presence of preeclampsia: (i) a blood pressure of
≥ 160/110 mmHg after 20 wk of pregnancy; (ii)
platelet count of less than 100,000 per microliter;
(iii) an increase in liver enzymes twice normal; (iv)
elevation of creatinine higher than 1.1 mg/dl or
doubling of baseline; and (v) headache, blurred
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vision, and epigastric pain. Eclampsia itself was
diagnosed based on the American College of
Obstetricians and Gynecologists’ Guideline (14).
On the other hand, the exclusion criteria were:
(i) known chronic diseases including cardiac, pul-
monary, renal, connective tissue disorders, hepatic
diseases, and hyperthyroidism; (ii) bodymass index
of > 30 or < 18.5; (iii) diabetes; (iv) history of
peripartum cardiomyopathy, heart valve disease,
and severe electrocardiographic abnormalities; (v)
consumption of cardiacmedication; and (vi) chronic
hypertension. The control group was selected from
the mothers with normal pregnancy (i.e., with no
history of any disease in these women and did
not develop any complications during pregnancy
or labor).
A checklist containing maternal age, gravid-
ity, gestational age, systolic and diastolic blood
pressure, number of previous pregnancies, body
mass index, and drug consumption was filled. To
evaluate the serumBNP level, 2–4 cc venous blood
samples were collected from the preeclampsia
(before the administration of magnesium sulfate)
and control groups in the biochemistry tube (gelled)
stored at 4°C in the refrigerator and sent to the
laboratory. After being exposed to ambient tem-
perature for 30 min, pro-BNP was measured using
VIDAS® NT-proBNP2 kit (Biomerieux, France) and
advanced enzyme-linked immunosorbent assay.
In addition, to determine the electrocardiographic
variations, all patients were subjected to a standard
b-mode transthoracic echocardiography (Samsung
V10 model) performed by a single cardiologist who
was blind to the patient’s status regarding blood
pressure. The echocardiography was conducted
before the administration of magnesium sulfate.
2.1. Ethical consideration
This study was approved by the Research Chan-
cellor of Mashhad University of Medical Sciences,
Mashhad, Iran (940284). Ethical Committee of
Mashhad University of Medical Sciences approved
the ethical issues regarding the involvement
of human subjects (IR.MUMS.fm.REC.1394.355).
Informed consent was obtained from all partici-
pants.
2.2. Statistical analysis
Data analyses were performed using Statistical
Package for the Social Sciences, version 16.0, SPSS
Inc, Chicago, Illinois, USA (SPSS). The relationship
between the qualitative and quantitative variables
was evaluated using the student t-test, and Mann-
Whitney U test. ANCOVA was used to control con-
founders. Furthermore, the correlation between
the quantitative variables was estimated through
Spearman’s rank correlation coefficient. All tests
were two-tailed and P-value less than 0.05 was
considered statistically significant.
3. Results
Overall, 94 pregnant women (i.e., 44 participants
with severe preeclampsia and 50 participants with
a normal pregnancy) were studied. Except for
age and gestational age, there was no significant
difference between the normal and preeclampsia
groups (Table I). The mean pro-BNP levels in the
women with preeclampsia (480.36 ± 754.52 pg/dl)
were significantly higher than women with normal
pregnancy (67.46 ± 106.24 pg/dl, Mann-Whitney
Test, p < 0.001). However, after controlling for age
and gestational age, this difference was diminished
(ANCOVA, p = 0.69).
There was no significant difference between the
two groups (neither before or after controlling for
age and gestational age as confounders) in terms
of the cardiac parameters, including EF, LVEDD
and LVESD, TAPSE which is an indicator of the
right ventricular systolic function, and ratio of the
early transmitral flow velocity to the early diastolic
tissue velocity (E/Em) which is an index for the left
ventricular diastolic function (Table II). Considering
EF ≥ 55%, LVEDD < 5.3, TAPSE ≥ 1.7, and E/Em ≤
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8 as normal values, and categorizing quantitative
variables into dichotomous ones, it was revealed
that although all echocardiographic indices were
more frequently abnormal in women with severe
preeclampsia than women with normal pregnancy,
no statistically significant difference was found
(Figure 1). The serum BNP level had a negative
correlation with EF (r = -0.39, p = 0.008), TAPSE (r = -
0.47, p = 0.001) and a positive correlation with E/Em
ratio (r = 0.48, p = 0.001), LVEDD (r = 0.15, p = 0.30),
and LVESD (r = 0.11, p = 0.47) in patients with severe
preeclampsia (Figure 2).
Table I. Comparison of the demographic variables between the patients with severe preeclampsia and normal pregnancy
Normal pregnancy (n = 50) Severe preeclampsia (n = 44) p-Value
Age (yr) 26.46 ± 6.00 30.86 ± 7.01 0.001
Gestational age (wk) 38.60 ± 1.86 33.60 ± 4.64 0.001
Body mass index (kg/m2) 29.69 ± 6.27 27.32 ± 5.33 0.55
Parity (n) 2.34 ± 1.17 2.63 ± 1.61 0.33
Note: All data are reported as mean ± SD; Student t-test was used for comparison
Table II. Comparison of echocardiographic indices in the study groups
Normal pregnancy (n = 50) Severe preeclampsia (n = 44) p-value
Ejection fraction (%) 57 (55–60) 55 (55–60) 0.25
Left ventricular end-systolic diameter (cm) 3.1 (2.9–3.2) 3.1 (2.9–3.3) 0.28
Left ventricular end-diastolic diameter
(cm)
4.7 (4.4–4.9) 4.5 (4.4–4.9) 0.94
Tricuspid Annular Plane Systolic
Excursion (cm)
2.2 (1.9–2.5) 2.1 (1.9–2.2) 0.07
E/Em(ratio) 9 (7–11) 10 (8.0–12.7) 0.06
Note: All data are reported as Median (IQR); Mann-Whitney test was used for comparison
Figure 1. Comparison of abnormal echocardiographic indices (ejection fraction (EF), tricuspid annular plane systolic excursion
(TAPSE), E/Em ratio, left ventricular end-diastolic diameter (LVEDD)) in the two study groups.
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Figure 2. Scatter plot for the correlation of ejection fraction (EF), tricuspid annular plane systolic excursion (TAPSE), E/Em ratio,
left ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter (LVESD) with blood natriuretic peptide
(BNP) level in patients with severe preeclampsia.
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4. Discussion
The aim of this study was to compare serum BNP
levels in the patients with severe preeclampsia
and normal pregnancy group. We also determined
the relationship of serum BNP level with the left
ventricular systolic and diastolic dysfunction in the
patients with severe preeclampsia. In the present
study, the mean total pro-BNP level showed an
increase in patients with severe preeclampsia in
comparison to the normal pregnancy group. How-
ever, after adjusting for maternal and gestational
age statistical differences was not seen. Addi-
tionally, some echocardiographic indices, such
as E/Em ratio, LVEDD, and LVESD, had a posi-
tive correlation with BNP in patients with severe
preeclampsia. These findings suggested that BNP
can be used as a marker for the diagnosis of
cardiac complications. On the other hand, EF and
TAPSE had a negative correlation with BNP in
patients with severe preeclampsia. It should be
noted that the mean NT-pro BNP level obtained in
the present study was higher than those reported
in previous studies (13, 15). However, there was
no significant difference between the two groups
in terms of underlying heart disease and renal
function. The possible reason of obtaining a high
mean BNP in the present study in comparison
to those obtained in the other studies could be
ascribed to high levels of BNP in two patients with
preeclampsia who had left ventricular dysfunction
and a significant reduction in EF ratio. These two
patients had no known underlying heart disease,
and we could not find any etiology for their condi-
tion during the investigation. Therefore, they were
not excluded from the study, and it was assumed
that high BNP and cardiac findings of these two
patients might be affected by their preeclampsia
severity.
In a study conducted by Resnik and colleagues
in 2005, the BNP levels of 25 healthy preg-
nant women with 34 preeclamptic women were
compared. In the mentioned study, the median
levels of BNP in the normal subjects and the
patients with moderate and severe preeclampsia
were 17.8, 21.1, and 101 pg/ml, respectively. ”This
finding indicated the significantly higher level of
this hormone in the severe preeclampsia group
than that in the mild preeclampsia group, which
could reflect the ventricular stress or subclinical
cardiac disorder associated with preeclampsia”
(15).
There are different studies examining the asso-
ciation of BNP with the severity of preeclampsia.
For instance, Bakacak and colleagues conducted
a study on 49 females with preeclampsia, 25 of
whom had severe preeclampsia, and 27 pregnant
women with normal blood pressure (16). ”Their
findings showed that serumNT-pro BNP level in the
preeclampsia group was significantly higher than
that in the control group. In addition, the NT-pro
BNP level was significantly higher in the severe
preeclampsia group than those in non-severe
preeclampsia and control groups”. Therefore, the
mentioned study concluded the NT-pro BNP level
as a useful marker for estimating the severity of
preeclampsia (16).
Hamad and colleagues also performed a study
in 2009 on 35 pregnant women with preeclampsia
and 30 females with normal pregnancy. They
performed echocardiography and estimated the
NT-pro-BNP, C-reactive protein, cystatin C, and
troponin I level during pregnancy and 3–6 months
after the delivery. The results demonstrated that
the function and dimensions of the left ventricle
and atria were significantly different between the
two groups. In addition, they reported a significant
increase in the septal and lateral E/Em ratio in the
preeclampsia group. Also, the levels of NT-pro-BNP
and cystatin C were demonstrated to significantly
elevate in the preeclampsia group (13). However,
we did not find a statistically significant difference
between the two groups regarding cardiac indices
which could be due to the period of exposure
with preeclampsia (i.e., from diagnosis to cessation
of pregnancy. Also, in previous reports, patients
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with early onset preeclampsia were studied but
in our study, patients with severe eclampsia at all
gestational ages were included.
In another study conducted by Fayers and col-
leagues in 2013, the BNP levels and echocardio-
graphic variations of 52 patients with preeclampsia
and 63 healthy pregnant women were investigated
(17). The results were indicative of the elevated
level of BNP in the females with preeclampsia
along with changes in the left ventricular dias-
tolic function as compared with the females with
normal pregnancy. Our results were similar to
those reported by Fayers and colleagues (17) in
terms of the enhancement of pro-BNP levels in the
preeclampsia group. Nonetheless, the examination
of cardiac parameters based on echocardiogra-
phy revealed that the two groups of preeclamp-
sia and normal pregnancy showed no significant
difference in this regard. However, in the severe
preeclampsia group, BNP levels had a significant
correlation with EF, TAPSE, and E/Em. This could
be indicative of the right and left ventricular systolic
and diastolic dysfunction.
In a systematic review conducted on 12 studies in
2013, the BNP level was reported to be significantly
higher in the preeclampsia patients than that in
normal pregnancies. Additionally, in the mentioned
study, the high level of BNP was reported to
be associated with cardiovascular complications
and preterm delivery. However, the researchers of
the mentioned study suggested performing more
studies on the patients with preeclampsia in order
to obtain more accurate findings in this regard (1).
It is noteworthy that although there are some
studies investigating BNP and preeclampsia,
limited research has examined the relationship
between cardiac parameters in preeclampsia and
BNP levels. To the best of our knowledge, this
was the first study to evaluate the correlation of
BNP with cardiac indices in preeclampsia in the
east of Iran. We also suggest to include pregnancy
complications and neonatal outcome in future
studies.
5. Conclusion
In conclusion, the total mean Pro-BNP level was
not statistically different in patients with severe
preeclampsia in comparison to that in the normal
pregnancy. However, E/Em had a statistically posi-
tive correlation with BNP and EF and TAPSE had a
negative correlationwith BNP in severe preeclamp-
sia patients. So, BNP can be used as a predictor for
at least some of the main cardiac functional indices
in patients with severe preeclampsia.
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